Scientists of the University Medical Center Göttingen (UMG) have identified new interactions between pancreatic cancer cells and the immune system. The insights of the research group provide important approaches for innovative therapies. The findings a…
Within a large group of more than 700 patients treated with CAR T cell therapy, researchers found no evidence that the therapy itself caused any type of secondary cancer in the modified T cells, according to new analysis reported today in Nature Medici…
Engineered immune cells called CAR-T cells are used in the treatment of cancer. Researchers from Uppsala University have now discovered that CAR molecules can be transferred from the CAR-T cells to other T cells in the tumor microenvironment.
Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg-Kimmel Institute for Cancer Immunotherapy have developed a computer model to help scientists identify tumor-fighting immune cells in patients with lung cancer treated with immune check…
A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will respond to new therapies. The research, published in Clinical Cancer Research, found that measuring the interaction between two…
CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a patient’s own immune T cells and engineering them to recognize specific targets on the surface of the cancer cell.
A far shorter, simpler, and less toxic treatment protocol for patients with triple-negative breast cancer produced outcomes similar to the current standard of care, a clinical trial co-led by a UT Southwestern Medical Center researcher shows. The findi…
T-cells from the liver and lymph nodes show promising potential for future treatments of liver cancer, according to a new study. Researchers at Karolinska Institutet have investigated how immune cells react to tumor-specific antigens in the complex env…
Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF genes (RAS/BRAF wild-type) are typically treated with EGFR inhibitors. For those whose tumors also demonstrate HER2 amplificati…
Researchers from the University of Pittsburgh have developed a new way to grow T cells in the lab that enables them to live longer and better destroy cancer cells in a mouse model of melanoma compared to those grown in traditional growth media.
